series of untreated patients was not dissimilar to that with the original BCLC B subclassification system, with a progressive and significant (p < 0.0001; Fig. 1 ) decrease in the overall median patient survival from BCLC BI (25 months), BCLC BII (16 months), and BCLC BIII (9 months), although compared to our previous analysis this subclassification did not improve the overall patient prognostication [2, 4] . Moreover, we also tested the subclassification proposed by Kim et al. [5] (Fig. 2 ) and found that, although also this system identifies significantly different prognostic subclasses (p < 0.0001), the 2 intermediate subclasses (i.e., Child-Pugh class A patients outside the up-to-11 criterion [B2A] and Child-Pugh class B patients within the up-to-11 criterion [B2B]) had a strikingly similar overall median survivals (B1: 24 months, B2A: 12 months, B2B: 12 months, and B3: 5 months); therefore, we feel that this finding justifies and confirms the suggestion put forth by the authors of the study to unify the 2 intermediate subclasses (B2A and B2B) , once again decreasing the potential of a more subtle discriminatory ability of the proposed subclassification system [2, 5] .
All in all, our current results, when analyzed taking into account the reasoning expressed by Golfieri et al. [1] in their review article, further support the notion that the art of prognostication in patients with HCC is not simple or straightforward, and even more difficult is the task of selecting treatment strategies guided by these imperfect staging systems [1, 6] . Thus, we feel that, rather than striving to formulate, or to confirm, the prognostic capability of ever more refined staging and substaging systems, the efforts of clinicians should be aimed at identifying the main drivers of patient prognosis and using them to select the most appropriate therapeutic strategy, following a hierarchical approach to treatment. 
